髓源性抑制细胞：治疗靶点
Myeloid derived suppressor cells: Targets for therapy.
作者信息
Waldron Todd J, Quatromoni Jon G, Karakasheva Tatiana A, Singhal Sunil, Rustgi Anil K
机构信息
Gastroenterology Division; Department of Medicine; University of Pennsylvania; Philadelphia, PA USA ; Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA;
出版信息
Oncoimmunology. 2013 Apr 1;2(4):e24117. doi: 10.4161/onci.24117.
Abstract
The goal of achieving measurable response with cancer immunotherapy requires counteracting the immunosuppressive characteristics of tumors. One of the mechanisms that tumors utilize to escape immunosurveillance is the activation of myeloid derived suppressor cells (MDSCs). Upon activation by tumor-derived signals, MDSCs inhibit the ability of the host to mount an anti-tumor immune response via their capacity to suppress both the innate and adaptive immune systems. Despite their relatively recent discovery and characterization, anti-MDSC agents have been identified, which may improve immunotherapy efficacy.
摘要
通过癌症免疫疗法实现可测量反应的目标需要对抗肿瘤的免疫抑制特性。肿瘤用于逃避免疫监视的机制之一是髓源性抑制细胞（MDSC）的激活。在肿瘤衍生信号的激活下，MDSC通过抑制先天性和适应性免疫系统的能力来抑制宿主产生抗肿瘤免疫反应的能力。尽管MDSC相对较新才被发现和表征，但已经鉴定出抗MDSC药物，这可能会提高免疫治疗效果。
相似文献
1
Myeloid derived suppressor cells: Targets for therapy.髓源性抑制细胞：治疗靶点
Oncoimmunology. 2013 Apr 1;2(4):e24117. doi: 10.4161/onci.24117.
2
Myeloid-derived suppressor cells: The green light for myeloma immune escape.髓系来源的抑制性细胞：骨髓瘤免疫逃逸的绿灯
Blood Rev. 2016 Sep;30(5):341-8. doi: 10.1016/j.blre.2016.04.002. Epub 2016 Apr 12.
3
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.靶向肿瘤微环境中髓源抑制细胞（MDSCs）的免疫疗法
Front Immunol. 2021 Feb 4;11:585214. doi: 10.3389/fimmu.2020.585214. eCollection 2020.
4
Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.用于癌症免疫治疗的调节髓源性抑制细胞的纳米颗粒系统
Curr Top Med Chem. 2017;17(16):1843-1857. doi: 10.2174/1568026617666161122121412.
5
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.髓源性抑制细胞——提高免疫治疗疗效的战斗策略概述。
Oncoimmunology. 2015 Feb 3;4(1):e954829. doi: 10.4161/21624011.2014.954829. eCollection 2015 Jan.
6
Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and age-related chronic inflammatory disorders.植物化学物质抑制髓源性抑制细胞（MDSC）的免疫抑制功能：对癌症和与年龄相关的慢性炎症性疾病的影响。
Int Immunopharmacol. 2018 Aug;61:231-240. doi: 10.1016/j.intimp.2018.06.005. Epub 2018 Jun 9.
7
Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.脐带血来源的间充质基质细胞通过分泌 HLA-G 促进髓源性抑制细胞增殖，从而降低造血干细胞移植后急性移植物抗宿主病的发生。
Cytotherapy. 2020 Dec;22(12):718-733. doi: 10.1016/j.jcyt.2020.07.008. Epub 2020 Aug 15.
8
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.髓源性抑制细胞：肿瘤微环境中驱动免疫抑制的关键细胞
Adv Cancer Res. 2015;128:95-139. doi: 10.1016/bs.acr.2015.04.002. Epub 2015 May 12.
9
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.癌症免疫治疗的新时代：靶向髓系来源抑制细胞以克服免疫逃逸。
Front Immunol. 2020 Jul 30;11:1680. doi: 10.3389/fimmu.2020.01680. eCollection 2020.
10
Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.肿瘤中的髓源性抑制细胞：从机制到抗原特异性和微环境调节。
Front Immunol. 2020 Jul 22;11:1371. doi: 10.3389/fimmu.2020.01371. eCollection 2020.
引用本文的文献
1
USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment.USP15通过SMYD3/CCL2依赖的髓源性抑制细胞招募促进结直肠癌免疫逃逸。
Cancer Immunol Res. 2025 Aug 1;13(8):1226-1245. doi: 10.1158/2326-6066.CIR-24-1194.
2
The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.代谢重编程在肿瘤免疫微环境中的作用：肝细胞癌免疫治疗的机制和机遇。
Int J Mol Sci. 2024 May 21;25(11):5584. doi: 10.3390/ijms25115584.
3
Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies.结直肠癌中髓源性抑制细胞介导的免疫抑制机制及相关治疗
World J Gastrointest Oncol. 2024 May 15;16(5):1690-1704. doi: 10.4251/wjgo.v16.i5.1690.
4
Function of reactive oxygen species in myeloid-derived suppressor cells.活性氧物种在髓系来源的抑制性细胞中的功能。
Front Immunol. 2023 Aug 14;14:1226443. doi: 10.3389/fimmu.2023.1226443. eCollection 2023.
5
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.沙利度胺在胶质母细胞瘤治疗中的潜在应用：最新简要概述。
Metabolites. 2023 Apr 11;13(4):543. doi: 10.3390/metabo13040543.
6
Neutrophils: New Critical Regulators of Glioma.中性粒细胞：神经胶质瘤的新关键调控因子。
Front Immunol. 2022 Jul 4;13:927233. doi: 10.3389/fimmu.2022.927233. eCollection 2022.
7
Eugenol triggers CD11bGr1 myeloid-derived suppressor cell apoptosis endogenous apoptosis pathway.丁香酚通过内源性凋亡途径触发CD11bGr1髓源性抑制细胞凋亡。
RSC Adv. 2018 Jan 19;8(7):3833-3838. doi: 10.1039/c7ra13499a. eCollection 2018 Jan 16.
8
Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells.肝特异性过表达 Gab2 通过激活髓源抑制性细胞的免疫抑制作用加速肝癌进展。
Oncogene. 2022 Jun;41(24):3316-3327. doi: 10.1038/s41388-022-02298-7. Epub 2022 Apr 11.
9
Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma.全血中单核细胞来源的髓系抑制细胞增加预示着浆细胞骨髓瘤患者的预后不良。
J Clin Med. 2021 Oct 14;10(20):4717. doi: 10.3390/jcm10204717.
10
Targeting myeloid-derived suppressor cells for cancer therapy.靶向髓源性抑制细胞用于癌症治疗。
Cancer Biol Med. 2021 Aug 17;18(4):992-1009. doi: 10.20892/j.issn.2095-3941.2020.0806.
本文引用的文献
1
Polysaccharide from Lentinus edodes inhibits the immunosuppressive function of myeloid-derived suppressor cells.香菇多糖抑制髓源抑制性细胞的免疫抑制功能。
PLoS One. 2012;7(12):e51751. doi: 10.1371/journal.pone.0051751. Epub 2012 Dec 18.
2
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.化疗诱导髓系来源抑制细胞中组织蛋白酶 B 的释放激活 NLRP3 炎性小体并促进肿瘤生长。
Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2.
3
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.肿瘤相关巨噬细胞：在人类肺癌中的功能、表型及与预后的关联。
Am J Transl Res. 2012;4(4):376-89. Epub 2012 Oct 10.
4
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.诱导淋巴细胞减少后阻断髓系来源的抑制细胞可改善黑色素瘤小鼠模型中的过继 T 细胞治疗。
J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.
5
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.低剂量环磷酰胺联合吉西他滨节拍化疗可以在体内诱导抗肿瘤 T 细胞免疫。
Cancer Immunol Immunother. 2013 Feb;62(2):383-91. doi: 10.1007/s00262-012-1343-0. Epub 2012 Aug 25.
6
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.IL-23 和 IL-12 在维持隐性癌症平衡状态中的相反作用。
Cancer Res. 2012 Aug 15;72(16):3987-96. doi: 10.1158/0008-5472.CAN-12-1337. Epub 2012 Aug 6.
7
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.肿瘤诱导型一氧化氮合酶通过调节血管内皮生长因子的释放控制功能性髓源抑制细胞的诱导。
J Immunol. 2012 Jun 1;188(11):5365-76. doi: 10.4049/jimmunol.1103553. Epub 2012 Apr 23.
8
Myeloid suppressor cells and immune modulation in lung cancer.肺癌中的髓系抑制细胞与免疫调节。
Immunotherapy. 2012 Mar;4(3):291-304. doi: 10.2217/imt.11.178.
9
Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression.适配体介导的 IL4Rα 阻断触发 MDSC 凋亡并限制肿瘤进展。
Cancer Res. 2012 Mar 15;72(6):1373-83. doi: 10.1158/0008-5472.CAN-11-2772. Epub 2012 Jan 26.
10
Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells.瘤内注射 CpG 寡核苷酸可诱导髓源性抑制细胞的分化并降低其免疫抑制活性。
J Immunol. 2012 Feb 15;188(4):1592-9. doi: 10.4049/jimmunol.1101304. Epub 2012 Jan 9.
Zotero 插件